About the Webinar
Evotec has partnered with the Global Health Discovery Collaboratory (GHDC) to offer a high-throughput teratogenicity assessment platform using human induced pluripotent stem cell (iPSC) technology. This initiative aims to identify potential teratogenic effects of drug candidates early in the drug discovery process enabling proactive risk mitigation. By leveraging this technology, Evotec hopes to create safer drugs more efficiently.
In this collaborative webinar with the Gates Foundation, our speakers are introducing the assay platform and are presenting the current state of the initiative.
